Announcements Trials

Browse Landscape

Phase

Status

Withdrawn 1 Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cisplatin 517 Radiotherapy 378 Cyclophosphamide 368 Carboplatin 359 Capecitabine 342 Paclitaxel 337 Oxaliplatin 336 Gemcitabine 322 Docetaxel 317 Fluorouracil 291 Drug Therapy 277 Bevacizumab 249 apatinib 247 camrelizumab 219 Etoposide 201 Irinotecan 183 Doxorubicin 181 Leucovorin 164 Dexamethasone 161 pembrolizumab 155 Neoadjuvant Therapy 146 sintilimab 145 anlotinib 140 Blood Specimen Collection 140 Pemetrexed 138 Cytarabine 138 toripalimab 133 Surgical Procedures, Operative 131 Radiosurgery 131 S 1 (combination) 125

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × bisantrene × Clear all

NCT04989335 2023-11-28

Bisantrene Combination for Resistant AML

Sheba Medical Center

Phase 2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡